Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 4 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 6Breast 6Other hematologic neoplasm 4Lymphoid 3Head & Neck 3Plasma cell 2Other solid neoplasm 2Gynecologic 2Endocrine 2CNS 2Other neoplasm 1Myeloid 1Genitourinary 1Dermatologic 1

Conditions

Non-functioning Pituitary Adenoma 1Insulinoma 1Hyperinsulinism 1Congenital Hyperinsulinism 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Saline Solution × Endocrine × Clear all
NCT05005715 2021-08-13

Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery

Seoul National University Hospital

Phase 2 Unknown
64 enrolled
Endocrine

Non-functioning Pituitary Adenoma

NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡